panalo999 vip
American Addiction Centers Data Breach Exposes Personal Information: Murphy Law Firm Investigates Legal Claims
Trump Cabinet picks, appointees targeted by bomb threats and swatting attacks
MOLLY-MAE Hague has shared a brand new update about her fashion brand Maebe. The social media star faced major backlash recently after fans were left disappointed at failing to get their hands on the pieces amid with Molly herself admitting stock issues were "frustrating". It caused her to tell her fans that she would be working hard to improve the brand's stock levels in the New Year but it appears as though the mum-of-one has managed to sort it earlier. In a new update on the Maebe Instagram account, it was revealed that the brand had THREE brand new T-shirts available for sale. The Power Tee comes in three different colours - Black, White and Wine , a deep red colour. The T-shirts are already available to purchase with Molly's fans likely desperate to get their hands on the garments amid the recent issues. The Love Island alum, 25, launched Maebe - her quality range of staples including boxy jackets, adjustable-waist jeans and short-sleeve knit tops - earlier this year. Huge fan demand saw the garments sell-out completely in 24 minutes - while others took aim at the price point and quality. Molly recently took to her Instagram comments section as fans talked of their struggles to get their hands on the garments , which combine comfort with style. One potential buyer put: "I've never been interested quite frankly. "It's very over-priced for what it is, but I genuinely just liked the set! "It's a rubbish experience, it's just a game of whoever can type the fastest or who has their details saved, most shops allow you a bit of time to check out." The YouTube star - who already owns fake tan brand Filter - then directly commented underneath. In a candid reply she wrote: "I couldn't agree with you more on the stock front, it's really frustrating. "Unfortunately I just didn't back myself enough when we planned these quantities a very long time ago. "I promise you this is something I am in total agreement with you on and it's something that in the New Year we will improve upon now that we have an understanding of the demand. "I'm really sorry you feel let down - I'm learning as I go and will make this a better buying experience for you as soon as we can." EVER since Molly-Mae Hague, 25, walked into the Love Island villa back in 2019, I’ve always been a mega fan. After hearing the news that she was coming out with a fashion brand, of course I was excited. But as much as I hate to admit it, I’m disappointed. I understand that she’s launched Maebe as a more high class brand. I know it’s not going to be Shein quality. But with prices varying from £35 to £140, I’m definitely not impressed. Maebe’s “ultimate blazer” is priced at an eye-watering £140, whilst a very simple, plain white tee is a whopping £35. Not only this, but the “contour popper top” is £50, and a seemingly boring white shirt will set you back a whopping £65. And if that wasn’t bad enough, £90 for a pair of jeans? I understand paying £50 for a pair of good quality denims, but £90?! That’s incredibly steep considering you can get Levi’s, a well-established brand that’s been going for donkey years, for just a tenner more. So, will I be buying anything from Maebe? The only thing I can say to that is Maebe (definitely) not. by Abigail Wilson, Senior Digital WriterTrump Cabinet picks, appointees targeted by bomb threats and swatting attacksNBA teams enjoy showing appreciation to their fan bases, particularly when it’s holiday time. Few teams in sports support their communities more fervently than the Miami Heat , who hosted their 33rd annual Thanksgiving Celebration on Thursday. The team collaborated with organizations to distribute 600 Thanksgiving baskets and also give 450 hot meals to underserved families throughout Miami-Dade County. Advertisement It’s hard for NBA teams to maximize five consecutive off days, but the Heat (6-7) found some solace in giving back and honing its relationship with the fans. Miami hasn’t played since Monday and won’t suit up again until Sunday. “There actually have been a lot of tears — tears of joy, tears of gratitude,” Heat head coach Erik Spoelstra said Thursday. “This is our 33rd year doing this. ... It’s turned into more than it was 33 years ago. Now, it’s a festive party. “This is our backyard here, and to share on a day like this really is amazing.” Among other Heat luminaries in attendance: three-time All-Star Bam Adebayo , team president Pat Riley and Heat stalwarts Alonzo Mourning and Bob McAdoo. The spirit of giving in this holiday season👏 We hosted our 33rd annual Thanksgiving celebration at Miami Rescue Mission to provide meals for hundreds of underprivileged families in the community. pic.twitter.com/wsTIrR5oHV — Miami HEAT (@MiamiHEAT) November 21, 2024 Earlier in the week, Adebayo hosted his “Bam, Books and Brotherhood Thanksgiving Twist” event in Liberty City, where dozens of families received Thanksgiving meals, side dishes, photo opportunities and autographs. He said he enjoys such events every year and will never get tired of doing them. Bam Adebayo, A’ja Wilson and Udonis Haslem arriving for the Bam, Books and Brotherhood Thanksgiving Twist here in Liberty City pic.twitter.com/oUsAfSnsbe — Clay Ferraro (@ClayWPLG) November 20, 2024 “You gotta really mean it when you say it,” Adebayo said. “We see a lot of people that give to the community, but they don’t be there. The biggest thing I learned about U.D. (Udonis Haslem): He was always on the frontline when he does community work. I feel like that’s the biggest representation you can have — you being there.” At this time of the year — between the dishes, high-spirited crowds and charitable moments — what was the best moment of the entire afternoon? Advertisement Riley, who earlier this week learned the Los Angeles Lakers will honor him with a statue , reflected on how important it is for Heat culture to be an extension of the NBA community, no matter the fan base or location. “I think it’s important for any organization, any business,” Riley said. “You create an environment in which everybody can flourish, and that becomes a shared vision within the organization. That doesn’t mean that a lot of people sometimes don’t agree with it, but everybody gets on board, and that’s what the important thing is. “The NBA is a giving league. I think every franchise — from the front office right on down to the players association — has this kind of spirit in their communities. ... A lot of people are going to have a great holiday because of this.” The Heat still play basketball, right? On Sunday, the Heat will host the Dallas Mavericks (8-7) in their first game since Monday’s double-digit win over the Philadelphia 76ers . The Heat have played only five home games thus far, the fewest in the NBA. They’re aiming to reach .500 again but have won three of of their last five. The biggest key to Miami’s turnaround? Since Nov. 10, the Heat are fifth in defensive rating after ranking 20th. They will seek to either maintain or improve that footing against Dallas, which will be without Luka Dončić , who is expected to miss at least the next week with a wrist injury. Dallas enters this matchup with three consecutive wins after losing a season-worst four straight. The Mavericks rank seventh in overall net rating despite being a game over .500. Last season, the Heat lost both regular-season meetings, including a 19-point loss the last time the Mavericks visited South Florida. Dončić and teammate Kyrie Irving combined for 54 points in that matchup, and the latter should be comfortable picking up the slack Sunday. Irving is second on his team in points per game (24.3) and is enjoying the most efficient season of his career (career-high 54.5 percent shooting, 53.8 percent from 3). Such potency undoubtedly will test Miami’s improved defense. Advertisement That could be an opportunity for either Jimmy Butler or Tyler Herro to carry Miami’s offense and avoid the game getting out of hand. Butler recently returned from a four-game absence with 30 points and 10 rebounds. In the two losses to Dallas last season, he averaged only 13 points. Herro is maintaining a career-high 24.2 points-per-game average, but he is shooting only 40.8 percent in his last three games. After Monday’s win, Butler jokingly called himself and Herro “1A and 1B” in terms of Miami’s scoring hierarchy. If both players catch fire on Sunday, it can help Miami reach .500 again, and the team (and its fans) could have a bit more to be grateful for as the holiday season unfolds. (Top photo: Issac Baldizon / Getty Images)
The New Yorker Argues Hoover's FBI Was 'Nonpartisan', Trips Over Community Note With THEIR OWN Reporting
By Hannah Fry, Los Angeles Times (TNS) Every day millions of people share more intimate information with their accessories than they do with their spouse. Wearable technology — smartwatches, smart rings, fitness trackers and the like — monitors body-centric data such as your heart rate, steps taken and calories burned, and may record where you go along the way. Like Santa Claus, it knows when you are sleeping (and how well), it knows when you’re awake, it knows when you’ve been idle or exercising, and it keeps track of all of it. People are also sharing sensitive health information on health and wellness apps , including online mental health and counseling programs. Some women use period tracker apps to map out their monthly cycle. These devices and services have excited consumers hoping for better insight into their health and lifestyle choices. But the lack of oversight into how body-centric data are used and shared with third parties has prompted concerns from privacy experts, who warn that the data could be sold or lost through data breaches, then used to raise insurance premiums, discriminate surreptitiously against applicants for jobs or housing, and even perform surveillance. The use of wearable technology and medical apps surged in the years following the COVID-19 pandemic, but research released by Mozilla on Wednesday indicates that current laws offer little protection for consumers who are often unaware just how much of their health data are being collected and shared by companies. “I’ve been studying the intersections of emerging technologies, data-driven technologies, AI and human rights and social justice for the past 15 years, and since the pandemic I’ve noticed the industry has become hyper-focused on our bodies,” said Mozilla Foundation technology fellow Júlia Keserű, who conducted the research. “That permeates into all kinds of areas of our lives and all kinds of domains within the tech industry.” The report “From Skin to Screen: Bodily Integrity in the Digital Age” recommends that existing data protection laws be clarified to encompass all forms of bodily data. It also calls for expanding national health privacy laws to cover health-related information collected from health apps and fitness trackers and making it easier for users to opt out of body-centric data collections. Researchers have been raising alarms about health data privacy for years. Data collected by companies are often sold to data brokers or groups that buy, sell and trade data from the internet to create detailed consumer profiles. Body-centric data can include information such as the fingerprints used to unlock phones, face scans from facial recognition technology, and data from fitness and fertility trackers, mental health apps and digital medical records. One of the key reasons health information has value to companies — even when the person’s name is not associated with it — is that advertisers can use the data to send targeted ads to groups of people based on certain details they share. The information contained in these consumer profiles is becoming so detailed, however, that when paired with other data sets that include location information, it could be possible to target specific individuals, Keserű said. Location data can “expose sophisticated insights about people’s health status, through their visits to places like hospitals or abortions clinics,” Mozilla’s report said, adding that “companies like Google have been reported to keep such data even after promising to delete it.” A 2023 report by Duke University revealed that data brokers were selling sensitive data on individuals’ mental health conditions on the open market. While many brokers deleted personal identifiers, some provided names and addresses of individuals seeking mental health assistance, according to the report. In two public surveys conducted as part of the research, Keserű said, participants were outraged and felt exploited in scenarios where their health data were sold for a profit without their knowledge. “We need a new approach to our digital interactions that recognizes the fundamental rights of individuals to safeguard their bodily data, an issue that speaks directly to human autonomy and dignity,” Keserű said. “As technology continues to advance, it is critical that our laws and practices evolve to meet the unique challenges of this era.” Consumers often take part in these technologies without fully understanding the implications. Last month, Elon Musk suggested on X that users submit X-rays, PET scans, MRIs and other medical images to Grok, the platform’s artificial intelligence chatbot, to seek diagnoses. The issue alarmed privacy experts, but many X users heeded Musk’s call and submitted health information to the chatbot. While X’s privacy policy says that the company will not sell user data to third parties, it does share some information with certain business partners. Gaps in existing laws have allowed the widespread sharing of biometric and other body-related data. Health information provided to hospitals, doctor’s offices and medical insurance companies is protected from disclosure under the Health Insurance Portability and Accountability Act , known as HIPAA, which established federal standards protecting such information from release without the patient’s consent. But health data collected by many wearable devices and health and wellness apps don’t fall under HIPAA’s umbrella, said Suzanne Bernstein, counsel at Electronic Privacy Information Center. “In the U.S. because we don’t have a comprehensive federal privacy law ... it falls to the state level,” she said. But not every state has weighed in on the issue. Washington, Nevada and Connecticut all recently passed laws to provide safeguards for consumer health data. Washington, D.C., in July introduced legislation that aimed to require tech companies to adhere to strengthened privacy provisions regarding the collection, sharing, use or sale of consumer health data. In California, the California Privacy Rights Act regulates how businesses can use certain types of sensitive information, including biometric information, and requires them to offer consumers the ability to opt out of disclosure of sensitive personal information. “This information being sold or shared with data brokers and other entities hypercharge the online profiling that we’re so used to at this point, and the more sensitive the data, the more sophisticated the profiling can be,” Bernstein said. “A lot of the sharing or selling with third parties is outside the scope of what a consumer would reasonably expect.” Health information has become a prime target for hackers seeking to extort healthcare agencies and individuals after accessing sensitive patient data. Health-related cybersecurity breaches and ransom attacks increased more than 4,000% between 2009 and 2023, targeting the booming market of body-centric data, which is expected to exceed $500 billion by 2030, according to the report. “Nonconsensual data sharing is a big issue,” Keserű said. “Even if it’s biometric data or health data, a lot of the companies are just sharing that data without you knowing, and that is causing a lot of anxiety and questions.” ©2024 Los Angeles Times. Visit at latimes.com. Distributed by Tribune Content Agency, LLC.
Watch Wicked Movie’s ‘What Is This Feeling?’ Performance by Ariana Grande & Cynthia Erivo By has released a , showing off and ‘s performance of “What Is This Feeling?” from the recently released movie. What happens in the Wicked video? The new video shows off the performance of “What Is This Feeling?” in its entirety. The song itself is about Galinda (Grande) and Elphaba (Erivo) rooming together at Shiz University, and their initial disdain for one another as they get to know each other. Check out the song below: The movies are directed by Jon M. Chu from a screenplay written by the musical’s book writer Winnie Holzman. It is based on Gregory Maguire’s bestselling novel and the Tony-winning stage musical. The ensemble cast is led by Ariana Grande and Cynthia Erivo, who play Galinda Upland and Elphaba Thropp in the film, respectively. The rest of the cast includes Michelle Yeoh as Madame Morrible, Jonathan Bailey as Fiyero Tigelaar, Jeff Goldblum as the Wizard of Oz, Peter Dinklage as Doctor Dillamond, Bowen Yang as Pfannee, Keala Settle as Miss Coddle, Marissa Bode as Nessarose Thropp, Bronwyn James as ShenShen, Ethan Slater as Boq, and more. “The film tells the untold story of the witches of Oz: Elphaba, a young woman, misunderstood because of her unusual green skin, who has yet to discover her true power; and Glinda, a popular young woman, gilded by privilege and ambition, who has yet to discover her true heart,” reads the official synopsis. “The two meet as students at Shiz University in the fantastical Land of Oz and forge an unlikely but profound friendship. Following an encounter with The Wonderful Wizard of Oz, their friendship reaches a crossroads and their lives take very different paths. Glinda’s unflinching desire for popularity sees her seduced by power, while Elphaba’s determination to remain true to herself, and to those around her, will have unexpected and shocking consequences on her future. Their extraordinary adventures in Oz will ultimately see them fulfill their destinies as Glinda the Good and the Wicked Witch of the West.” Wicked: Part One is out now in theaters. The sequel, , is currently set for November 21, 2025. Anthony Nash has been writing about games and the gaming industry for nearly a decade. When he’s not writing about games, he’s usually playing them. You can find him on Twitter talking about games or sports at @_anthonynash. Share article-3810109 is an antibody commercialized by , with a leading Phase II program in Human Immunodeficiency Virus (HIV) Infections (AIDS). According to Globaldata, it is involved in 4 clinical trials, of which 3 were completed, and 1 is ongoing. Smarter leaders trust GlobalData The gold standard of business intelligence. The revenue for -3810109 is expected to reach an annual total of $132 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress. GSK-3810109 Overview -3810109 is under development for the treatment of human immunodeficiency virus (HIV) infections. The drug candidate is a broadly neutralizing antibody acts by targeting gp120. It is administered through intravenous or subcutaneous route. GSK Overview is a healthcare company that focuses on developing, manufacturing and commercializing general medicines, specialty medicines and vaccines. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular, and urogenital, anti-bacterial, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastrointestinal diseases. ’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. is headquartered in Brentford, Middlesex, the UK. The company reported revenues of (British Pounds) GBP30,328 million for the fiscal year ended December 2023 (FY2023), an increase of 3.4% over FY2022. In FY2023, the company’s operating margin was 22.2%, compared to an operating margin of 21.9% in FY2022. In FY2023, the company recorded a net margin of 16.2%, compared to a net margin of 51% in FY2022. The company reported revenues of GBP7,884 million for the second quarter ended June 2024, an increase of 7.1% over the previous quarter. For a complete picture of -3810109’s valuation, From Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors. , the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company. The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s .SNP backs calls for free bus travel to be scrapped for thug youngsters
Timeline: Jimmy Carter, 1924-2024
NBI-1076986 is a small molecule commercialized by , with a leading Phase I program in Movement Disorders. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. Smarter leaders trust GlobalData The gold standard of business intelligence. The revenue for NBI-1076986 is expected to reach an annual total of $13 mn by 2038 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress. NBI-1076986 Overview NBI-1076986 is under development for the treatment of movement disorders. It is administered through oral. The drug candidate acts by targeting muscarinic 4 receptor. Neurocrine Biosciences Overview (Neurocrine) is a biopharmaceutical company that discovers, develops, and markets neurological drugs. The company’s lead product Ingrezza, is a vesicular monoamine transporter 2 (VMAT2) inhibitor to treat adults with tardive dyskinesia and chorea associated with Huntington’s disease. It is developing a pipeline of drug candidates for various indications in neurology, neuroendocrinology, and neuropsychiatry. Neurocrine also conducts clinical trials and studies for diseases such as movement disorders, epilepsy, and congenital adrenal hyperplasia, among others. The company works in collaboration with and for products distribution. Neurocrine is headquartered in San Diego, California, the US. The company reported revenues of (US Dollars) US$1,887.1 million for the fiscal year ended December 2023 (FY2023), an increase of 26.8% over FY2022. In FY2023, the company’s operating margin was 13.3%, compared to an operating margin of 12% in FY2022. In FY2023, the company recorded a net margin of 13.2%, compared to a net margin of 10.4% in FY2022. The company reported revenues of US$590.2 million for the second quarter ended June 2024, an increase of 14.5% over the previous quarter. For a complete picture of NBI-1076986’s valuation, From Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors. , the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company. The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s .
Tafara Gapare propels Maryland men’s basketball to 91-67 romp over BucknellAre you tracking your health with a device? Here’s what could happen with the dataU.S. stocks climbed after market superstar Nvidia and another round of companies said they’re making even fatter profits than expected. The S&P 500 pulled 0.5% higher Thursday after flipping between modest gains and losses several times in the morning. The Dow Jones Industrial Average jumped 1.1%, and the Nasdaq composite edged up less than 0.1%. Banks, smaller companies and other areas of the stock market that tend to do best when the economy is strong helped lead the way, while bitcoin briefly broke above $99,000. Crude oil, meanwhile, continued to rise. Treasury yields edged higher in the bond market. On Thursday: The S&P 500 rose 31.60 points, or 0.5%, to 5,948.71. The Dow Jones Industrial Average rose 461.88 points, or 1.1%, to 43,870.35. The Nasdaq composite rose 6.28 points, or less than 0.1%, to 18,972.42. The Russell 2000 index of smaller companies rose 38.48 points, or 1.7%, to 2,364.02. For the week: The S&P 500 is up 78.09 points, or 1.3%. The Dow is up 425.36 points, or 1%. The Nasdaq is up 292.30 points, or 1.6%. The Russell 2000 is up 60.18 points, or 2.6%. For the year: The S&P 500 is up 1,178.88 points, or 24.7%. The Dow is up 6,180.81 points, or 16.4%. The Nasdaq is up 3,961.07 points, or 26.4%. The Russell 2000 is up 336.94 points, or 16.6%.
Risk adjusted net present value: What is the current valuation of AstraZeneca’s Eneboparatide?Mystery drone 'came within 250 metres of Royal Navy flagship HMS Queen Elizabeth'